Previous studies of cases and controls or selected patients demonstrated association of the ADRB1 Arg389Gly and ADRA2B I/D polymorphisms with blood pressure, measures of obesity, and/or serum lipids. In multivariate-adjusted analyses of 1881 subjects randomly recruited from a White population, ADRB1 ArgArg homozygotes, compared with Gly allele carriers, had higher diastolic blood pressure (79.4 vs 78.4 mm Hg; P ¼ 0.012), and higher serum high-density lipoprotein (HDL) cholesterol (1.33 vs 1.29 mmol l
À1
; P ¼ 0.020), whereas none of the other cardiovascular or metabolic phenotypes reached significance in relation to the two polymorphisms. Our family-based design excluded population stratification as a possible explanation for the significant association of the ADRB1 Arg389Gly polymorphism with blood pressure and HDL cholesterol.
The b1 (ADRB1) and a2B (ADRAB2) adrenergic receptors are important in the regulation of blood pressure (BP), cardiovascular function and lipid metabolism. Their genes locate to chromosomes 10q24-26 and 2p13-q13, respectively. The ADRB1 Arg389Gly polymorphism leads to the substitution of the amino acid arginine by glycine near to the intracellular carboxyl terminal, which is involved in G-protein binding. 1 The ADRA2B insertion/deletion (Ins þ 910Del (I/D)) polymorphism involves the deletion of three glutamic acids from a repeat element in the third intracellular loop of the protein.
2 ADRB1 Arg allele carriers have increased adenyl cyclase activity in response to agonists, such as isoproterenol, epinephrine and norepinephrine. 1 The ADRA2B deletion results in a loss of agonistpromoted desensitization. Case-control studies 1 and continuous trait analyses in patients with coronary heart disease 4 demonstrated association of the ADRB1 Arg389Gly polymorphism with hypertension 1 or with systolic 1 or diastolic 1,4 BP. However, none of these studies involved families randomly recruited from a general population. Furthermore, we previously demonstrated that in Chinese men the ADRA2B I allele was associated with higher BP, but with lower body mass index and waistto-hip ratio, and with less insulin resistance. 5 Several studies in diabetic 6 and non-diabetic 2,7 patients reported association of the ADRA2B I/D polymorphism with metabolic phenotypes. However, with the exception of our small Chinese Study (n ¼ 481), 5 none of these previous reports was ADRA2B involved a family-based population sample or assessed the population stratification as a possible explanation of significant phenotype-genotype associations.
In the present study, we investigated in a familybased cohort possible association of the ADRB1 Arg389Gly and ADRA2B I/D polymorphisms with BP and metabolic phenotypes, analysed as continuous traits. For analysis, we applied a variance decomposition method, which is robust to population stratification or admixture. The University of Leuven Ethics Committee approved the Flemish Study on Environment, Genes and Health Outcomes. 8 From August 1985 until December 2006, we randomly recruited 2165 subjects from a geographically defined area in Northern Belgium. 8 The participation rate averaged 64.3%. All participants gave informed written consent. We excluded 284 subjects from analysis, because their DNA could not be extracted or genotyped (n ¼ 42), because of Mendelian inconsistency (n ¼ 22), because participants were younger than 18 years (n ¼ 200), or because of important co-variables had not been measured (n ¼ 20). Thus, the number of subjects statistically analysed totalled 1881.
At the enrolment home visit, trained nurses measured BP and anthropometric characteristics. They also administered a questionnaire to collect information about each subject's medical history, smoking and drinking habits, and intake of medications. BP was the average of five consecutive readings. Body mass index was weight in kilograms divided by the square of height in metres. The waistto-hip ratio, determined by means of a tape measure, was the smallest circumference at the waist divided by the largest circumference at the hip. We measured serum total and high-density lipoprotein (HDL) cholesterol and genotyped the ADRAB1 Arg389Gly and ADRA2B I/D polymorphisms (genotyping methods available as Supplementary Information). Hypertension was a BP of at least 140 mm Hg systolic or 90 mm Hg diastolic or use of anti-hypertensive drugs.
For statistical analysis, we used SAS software, version 9.1.3 (SAS Institute, Cary, NC, USA). We compared means and proportions by the standard normal z-test and the w 2 -statistic, respectively. We searched for possible covariates of the phenotypes under study, using stepwise multiple regression analysis with the P-value for independent variables to enter and stay in the models set at 0.15. In population-based analyses, we tested phenotypegenotype associations, using the PROC MIXED procedure of the SAS package, while adjusting for co-variables and family clusters. We tested for heterogeneity, using appropriate interaction terms. In family-based analyses, we evaluated the within-and between-family components of phenotypic variance, using the orthogonal model proposed by Abecasis et al. The study population consisted of 1802 relatives from 175 families and 79 unrelated subjects. Mean values were 45.5 years for age and 124.7 and 76.9 mm Hg for systolic and diastolic BP, respectively. The study sample included 525 (27.9%) hypertensive patients, of whom 281 were on anti-hypertensive drugs. Women compared to men had lower BP and less frequently reported smoking and alcohol consumption (Supplementary Table) . The frequencies of the ADRB1 genotypes (ArgArg 56.2%, ArgGly 36.9% and GlyGly 6.9%; P ¼ 0.66) and the ADRA2B genotypes (II 45.7%, ID 41.7%, and DD 12.5%; P ¼ 0.05) did not deviate from Hardy-Weinberg proportions. Table 1 shows the multivariate-adjusted phenotypegenotype associations for the two polymorphisms in the population-based analyses, which accounted for family clusters. Both before and after adjustment (Table 1) for co-variables, ADRB1 Arg homozygotes, compared with Gly allele carriers, had higher diastolic BP (79.4 vs 78.4 mm Hg; P ¼ 0.012) and higher serum HDL cholesterol (1.33 vs 1.29 mmol l À1 ; P ¼ 0.020). Otherwise, none of the phenotype-genotype associations for both genes under study reached statistical significance. Furthermore, a sensitivity analysis by sex did not reveal significant heterogeneity. Considering both single-nucleotide polymorphisms (SNPs) together, with or without their interaction, did not significantly improve the fit of the mixed models. This was also the case, when we applied an additive model for the ADRA2B I/D polymorphism (PX0.24).
Our family-based analyses included 175 pedigrees, of which 72 spanned more than two generations. We adjusted the family-based analyses as in Table 1 . For both the ADRB1 Arg389Gly and ADRA2B I/D polymorphisms, the orthogonal model did not reveal significant population stratification for any phenotype-genotype association (PX0.23 and PX0.32, respectively). The effect size ( ± s.e.) of the transmission of the ADRB1 Gly allele from parents to informative offspring was À0.33 mm Hg (n ¼ 906; P ¼ 0.64) for diastolic BP and À0.045 mmol l
(n ¼ 906; P ¼ 0.07) for HDL cholesterol.
The key finding of our study was that in the absence of population stratification diastolic BP and serum HDL cholesterol were weakly but significantly lower in ADRB1 Gly allele carriers than in ArgArg homozygotes. However, we could not replicate the association of BP and the metabolic phenotypes with ADRA2B I/D polymorphism.
Several tissues, including adipocytes, cardiac myocytes and kidney cells, express ADRB1. Its activation increases BP, stimulates lipolysis, 10 enhances myocardial contractility, 1 and stimulates the release of renin. 1 In transfected Chinese hamster fibroblasts, the ADRB1 Arg389Gly variant affects the receptor's ability to bind the Gs molecule. 11 The SNP is a 'loss-of-function' polymorphism with the ArgArg homozygotes exhibiting a three-to fourfold higher isoprenaline-stimulated adenylyl cyclase Table 1 Phenotype-genotype associations in population-based analyses The waist-to-hip ratio is the smallest circumference at the waist divided by the largest circumference at the hip level. To convert values for total and HDL cholesterol to milligrams per 100 ml, divided by 0.02586. activity than the Gly389 variant due to a better coupling of the Arg389 to Gs protein than the Gly389 variant.
11
On the basis of these experimental evidences, we speculated that ADRB1 ArgArg homozygotes might be more responsive to sympathetically mediated increase in peripheral resistance. If these hypotheses were true, it might explain the slight increase in diastolic BP as observed in the present study, peripheral arterial resistance being the main determinant of diastolic BP. In line with our current findings, the Arg389Gly polymorphism in ADRB1 might be a potential pharmacogenetic target. Indeed, ADRB1 ArgArg homozygotes are more sensitive to b-blockers, or to b1-adrenergic agonist activity.
12 ADRB1 stimulation activates lipolysis. 1 We hypothesize that facilitated signal transduction after stimulation of the b1-adrenergic receptor 1 might explain the higher serum HDL cholesterol level in ADRB1 ArgArg homozygotes.
Although functional, the evidence linking the ADRA2B I/D polymorphism with BP and metabolic phenotypes remains equivocal. In our previous family-based study in Chinese, 5 we found associations only in men, but not in women. Other studies of the ADRA2B I/D polymorphism mainly involved selected groups of patients. 2, 7 In addition to selection, small sample size and the possibility of undetected population stratification limit the interpretation of most ADRA2B study in humans.
In conclusions, our study showed a weak but statistically significant association of diastolic BP and HDL cholesterol with the ADRB1 Arg389Gly polymorphism in the absence of population stratification, whereas the ADRA2B polymorphism does probably not contribute much to the variation of BP and metabolic phenotypes in unselected White Europeans.
